Takeda Pharmaceutical (TAK) Expected to Post Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to be issuing its Q2 2027 results before the market opens on Thursday, October 29th. Analysts expect Takeda Pharmaceutical to announce earnings of $0.1450 per share and revenue of $7.34 billion for the quarter. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. The business had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. On average, analysts expect Takeda Pharmaceutical to post $1.56 EPS for the current fiscal year and $1.40 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $20.29 on Wednesday. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $20.55. The business has a 50 day simple moving average of $18.72 and a 200 day simple moving average of $17.49.

Analyst Ratings Changes

A number of brokerages have weighed in on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Zacks Research cut Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 1st. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Insider Buying and Selling

In related news, General Counsel Anne Furney sold 30,868 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $527,842.80. Following the completion of the sale, the general counsel owned 204,298 shares of the company’s stock, valued at $3,493,495.80. This trade represents a 13.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Julie Kim sold 89,090 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $1,523,439.00. Following the completion of the sale, the chief executive officer directly owned 391,489 shares of the company’s stock, valued at $6,694,461.90. This trade represents a 18.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 627,457 shares of company stock valued at $10,981,175. Insiders own 0.04% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.